1. GSK allies with Innovax for COVID-19 vaccine R&D project— Zentalis Pharma raises $165M in IPO — Drug discovery in the age of coronavirus — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

BREZTRI launch

Discussion in 'Boehringer Ingelheim' started by anonymous, Feb 12, 2020 at 8:57 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    not to be a doom and gloomier, word on street is pretty good for last trial. Two triples barking down our throats out there... I guess we just push the tio MIST. Any managers without heads in sand, any plan?
     

  2. anonymous

    anonymous Guest

    The company is just squeezing out the last bit of juice on SP. ST market share sucks and the Triples will kill the LAMA/LABA market even more

    The show is almost over. We will lose coverage on a few more plans and then it will just snowball

    At least we as reps have all the leverage. Our DMs have to kiss our azz. Who else are they going to hire if we are gone? Lmaoooo
    Seriously what good rep can you entice to come here with a completely empty pipeline and maybe 2 years left in this division. It’s like a short term contract job
     
  3. anonymous

    anonymous Guest

    The plan is for is to continue to differentiate triple from LAMA/LABA class and then to further differentiate Stiolto from the rest of the LAMA/LABAs. It is the current plan and this holds true regardless of what happens in the triple class. There is value in the lama/laba class and guidelines support this position. So quit whining and do what you’re paid to do.
     
  4. anonymous

    anonymous Guest

    oh ok. That has been working soooo well for the past several years hasn’t it. But this time we will really mean it and this time doctors are gonna really listen lmao lol.
    Wonder why the LAMA/LABA market has flattened? Surely it’s not because of the Tripp’s option? What will happen with 2 companies pushing for Triple therapy that has better coverage and access than ST?

    Oh wait..wait...the guidelines say inhaled steroids cause pneumonia so that’ll stop them dead in their tracks. Lmao hahaha. Well except that they are either 1% or 0% sooo good luck with that Mr DM company man and your failing coverage
     
  5. anonymous

    anonymous Guest

    Word on the street for upper management not making sales calls: “MANAGED CARE COVERAGE is the new “Guideline”.”
     
  6. anonymous

    anonymous Guest

    Fact

    How many times have we heard docs say they write a drug only because they get it covered and they think it’s the last one they’d actually choose if given a choice?
     
  7. anonymous

    anonymous Guest

    Worthless excuses from worthless reps. Managed care coverage for our products are on par with the competition, with the small exception of some minor plans. Oh and that thing about your customers not wiring your products because of the notion that it’s not covered? Well, I would’ve thought you are more adept than that to overcome that basic objection. Apparently, not...so you worthless egoistic reps need to be retrained. I say, more role playing for you. Nice try though...
     
  8. anonymous

    anonymous Guest

    *writing
     
  9. anonymous

    anonymous Guest

    You’ve got to be kidding me lmao lolol
    Another DM company man on this board haha haha.

    OK Chief week its certainly amazing how GSK has double our market share in the LAMA/LABA market with all the inspiration matters sales pieces and dolls to show doctors and we only have half their coverage. Can you explain why that is happening nationally? I’m sure your reps territories are the only ones beating GSK right?

    Oh oh...don’t forget how Trelegy blew by us in the first 3 months of their launch. Can you believe it? I mean what about the GD guidelines? Hahahahah

    Please tell us more. Maybe you can get up on stage at the next meeting and show us how its done
     
  10. anonymous

    anonymous Guest


    Troll
     
  11. anonymous

    anonymous Guest

    I dread another triple
    The amount of Trelegy written is crazy alarming!! Another triple is just more share of voice for the use of a triple.
    Gonna be interesting to see how AZs triple does compared to GSKs.
    At least we will have a good view on the sidelines